Acute Myeloid Leukemia | Tumor

CURE’s acute myeloid leukemia page features the latest cancer news and updates on acute myeloid leukemia. Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in acute myeloid leukemia.

Ziftomenib Submits New Drug Application to FDA for R/R NPM1-Mutant AML

April 13th 2025, 6:00pm

Article

The FDA previously granted breakthrough therapy designation to ziftomenib for relapsed/refractory NPM1-mutant AML.

FDA Grants Positive Review for AML Drug Trial, First Dosing in 2025

April 8th 2025, 9:00pm

Article

The FDA granted a positive review for an acute myeloid leukemia drug trial, with initial dosing expected in 2025.

SLS009 May Improve Survival in R/R AML

April 8th 2025, 3:00pm

Article

SLS009 is associated with an improvement in survival among patients with relapsed/refractory acute myeloid leukemia.

First Patient Dosed With Annamycin and Cytarabine in Phase 3 AML Trial

April 1st 2025, 4:24pm

Article

The first patient with relapsed or refractory acute myeloid leukemia has been dosed with Annamycin plus Cytarabine in the global phase 3 MIRACLE trial.

On Alcohol Addiction for the Patient With Cancer

March 10th 2025, 5:00pm

Article

As a cancer survivor, I overcame alcohol addiction and urge others to seek support, safe detox and sobriety to improve their treatment and recovery.

Tuspetinib Triplet Is Safe and Has Antileukemic Activity in Newly Diagnosed AML

February 21st 2025, 2:00pm

Article

Treatment with tuspetinib in combination with Venclexta and Vidaza in newly diagnosed acute myeloid leukemia showed safety and antileukemic activity.

Breaking Down Cancer Therapies Approved by the FDA in January 2025

February 3rd 2025, 4:00pm

Article

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations like AML, MDS and breast cancer.

Galinpepimut-S Immunotherapy Has Preliminary Efficacy in Acute Myeloid Leukemia

January 30th 2025, 10:00pm

Article

Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission following second-line salvage therapy.

FDA Approves GRAFAPEX/Fludarabine Before alloHSCT in AML and MDS

January 24th 2025, 4:15pm

Article

The FDA has approved GRAFAPEX™ and fludarabine as a preparative regimen in acute myeloid leukemia or myelodysplastic syndrome prior to alloHSCT.

To Those Facing End of Life From Cancer

December 27th 2024, 6:00pm

Article

We, survivors, often express our gratitude for life, love, support and research, but what about the patients who do not experience positive outcomes from treatment?